Evaluation of Fiasp (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

    Not Recruiting
  • participants needed
  • sponsor
    Stanford University
Updated on 23 January 2021
hemoglobin a1c
glycosylated hemoglobin


This is a pilot outpatient study conducted at Stanford to obtain preliminary data on how Fiasp works in a closed-loop system and to determine if any changes need to be made to the 670G pump to optimize the use of Fiasp.


This will be a randomized cross-over blinded study and to see how the 670G pump responds to the introduction of Fiasp insulin. Subjects enrolled in the study will have a 2 week period of optimization with weekly assessments of their Carelink download before entering the blinded phase of the study. They will use their usual home insulin during the optimization phase. They will then be started on their first blinded insulin (aspart or Fiasp) which they will use for 2 weeks, before they cross-over to the other insulin.

Condition Insulin dependent diabetes mellitus
Treatment Fiasp, Novolog
Clinical Study IdentifierNCT03554486
SponsorStanford University
Last Modified on23 January 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note